Results on the treatment of uterine cervix cancer: ten years experience

The aim of the study is to present our experience in the treatment of uterine cervix cancer over the last decade. This is a retrospective study of 90 patients with cervical cancer treated in a University Department of Obstetrics and Gynecology from 1993 to 2002. After the disease was histologically confirmed and staged the patients were treated according to stage with surgery (S) radiotherapy (RT), RT alone or Chemoradiaton (C-RT). The course of the disease and follow-up was traced from patient notes and after a structured telephone questionnaire. Mean age of patients was 48 +/- 14.3 years (29-84). Nine of 90 patients (10%) were lost to follow-up. FIGO (1994) staging was I in 50% of patients, II in 33.5%, III in 13.5% and IV in 3%. The size of tumor was < or = 4 cm in 75%. Of the tumors 87% were of squamous histology and 13% adenocarcinomas. Patients were treated with cone biopsy (5.5%), type I hysterectomy pelvic RT (10%), radical (type II-III) hysterectomy and pelvic lymphadenectomy +/- radiotherapy (41%), RT alone in 38% and C-RT in 5.5%. Incidence of complications after surgery was 19.5% and after RT 12.5%. Mean follow-up was 41 +/- 19 months (6-110). Five-year survival in Stage I was 84%, Stage II 64% and Stage III 40%. A single patient with Stage IV disease is alive with disease after two years. In conclusion uterine cervical cancer has improved survival because of early diagnosis. Treatment should be individualized according to the status of disease. Surgery and RT had similar rates of complications.

Uterine cervical cancer; Treatment; Radical hysterectomy; Radiotherapy

[1] Parkin D.M., Pisani P., Ferlay J.: "Estimate of the worldwide incidence of 25 majors cancers in 1990". Int. J. Cancer, 1999, 80, 827.

[2] World Health Organization (WHO):'The world health reports 1998. Life in twenty first century". Geneva, World Health Organization, 1998, 1.

[3] Felay J., Black R.J., Pisani P. et al.: "Cancer in the European Union. Lyon". Int. Agency for Research on Cancer, 1996, 1, 1.

[4] Gibson L.,S piegelhalter D.J.,C amilleri-Fernante D.et al.: "Trends in invasive cervical cancer incidence in East Anglia from 1971- 1993". J. Med. Screen., 1997, 4, 44.

[5] Burghardt E., Ostor A., Fox H.: "The new FIGO definition of cervical cancer Stage IA: a critique". Gynecol. Oneal., 1997, 65, 1.

[6] Creasman W.: "New gynecologic cancer staging". Gynecol Oneal., 1995, 58, 157.

[7] Burghardt E., Webb M.J., Monaghan J.M. et al.: "Prognostic factor of cervical cancer". In: Burghardt E. "Surgical Gynecologic Oncology". Thieme, Stuttgart, Germany, 1993, 302.

[8] Chassagne D., Sismondi P., Horiot J.C. et al.: "A glossary for reporting complications of treatment in gynecological cancers" Radiother. Oneal., 1993, 26, 183.

[9] Bornstein J., Rahat M.A., Abramovici H.: "Etiology of cervical cancer, current concepts". Obstet. Gynecol. Survey, 1995, 50, 146.

[10] Petry K.U., Scheffel D., Bode U. et al.: "Cellular immunodeficiency enhances the progression of human papilloma-associated cervical lesions". Int. Cancer, 1994, 57, 836.

[11] Hatch K.D., Fu Y.S.: "Cervical and Vaginal cancer". In: Berek J.S. Novak's Gynecology. Williams & Wilkins, Baltimore USA, 1996, 1128.

[12] Bloss J.D., Berman M.L., Mukhererjee J. et al.: "Bulky Stage IB cervical carcinoma managed by primary radical hysterectomy followed by tailored radiotherapy". Gynecol. Oneal., 1992, 47, 21.

[13] Piver M.S., Rutledge F., Smith J.P.: "Five classes of extended hysterectomy for women with cervical cancer". Obstet. Gynecol., 1974, 44, 265.

[14] Webb M.J., Symmonds R.E.: "Site of recurrence of cervical cancer after radical hysterectomy". Am. J. Obstet. Gynecol., 1980, 138, 813.

[15] DiSaia P.J.: "Surgical aspects of cervical carcinoma". Cancer, 1981, 48, 548.

[16] Heller P.B., Barnh仆1 D.R., Mayer A.R. et al.: "Cervical carcmoma found incidentally in a uterus removed for benign indications". Obstet. Gynecol., 1986, 36, 187.

[17] Sartori E., Fallo L., La Face B. et al.: "Extended radical hysterectomy in early Stage carcinoma of the cervix". Int. Gynecol Cancer, 1995, 5, 143.

[18J Aoki Y., Sassaki M., Watanabe M. et al.: "High risk group in Node Positive Patients with Stage TB-TIA". Gynecol. Oneal., 2000, 77, 305.

[19] Morrice P., Castaigne D., Pautier P. et al.: "Interest of pelvic and paraaortic lymphadenectomy in patients with Stage IB and TI cervical cancer". Gynecol. Oneal., 1999, 73, 106.

[20] Landoni F., Maneo A., Colombo A. et al.: "Randomized study of radical surgery versus radiotherapy for Stage IB-IIA cervical cancer". Lancet, 1997, 350, 535.

[21] Piver M.S., Chung W.S.: "Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma". Obstet. Gynecol., 1975, 46, 507.

[22] Miller B.E., F lax S.D., Arheart K. et al.: "The presentation of adenocarcinoma of the uterine cervix". Cancer, 1993, 72, 1281.

[23] Hopkins M.P., Morley G.W.: "A comparison of adenocarcinoma and squamous cell carcinoma of the cervix". Obstet. Gynecol., 1991, 77, 912.

[24] Keys H.M., Bundy B.N., Stehman F.B. et al.: "Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage IB cervical carcinoma". N. Engl. J Med., 1999, 340, 1154.

[25] Whitney C.W., Sause W., Bundy B.N. et al.: "Randomized comparison of fluorouracil plus cisplatin vs. hydroxyurea as an adjunct to radiation therapy in Stage IIB-IVA carcinoma of the cervix". J. Clin. Oncol., 1999, 17, 1339.

[26] Chang C., Huey C., Hong J. et al.: "Randomized trial of Neoadjuvant CYB and radical hysterectomy versus radiation therapy for bulky IB-IIA cervical cancer". J. Clin. Ongol., 2000, 18, 1740.

[27] Landoni F., Maneo A., Cormio G. et al.: "Class II versus class III radical hysterectomy in Stage IB-IIA cervical cancer: a prospective randomized study". Gynecol. Oneal., 2001, 80, 3.

[28] Kinney W.K., Alvarez R.D., Reid G.C. et al.: "Value of adjuvant whole pelvic irradiation after Wertheim hysterectomy for early stage squamous carcinoma of the cervix with pelvic node metastasis". Gynecol. Oncol., 1989, 34, 258.

[29] Magrina J.F., Goodrich M., Weaver A. et al.: "Modified radical hysterectomy. Morbifity and Mortality". Gynecol. Oncol., 1995, 59, 277.

[30] Van Nagell J.R., Parker J.C., Maruyama Y. et al.: "Bladder or rectal injury following radiation therapy for cervical cancer". Am. J. Obstet. Gynecol., 1974, 119, 727.